On July 15, Hengrui Medicine and Kailera Therapeutics of the United States jointly announced that the Phase III clinical trial (HRS9531-301) of HRS9531 injection, a dual receptor agonist of glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP), for the treatment of obese or overweight subjects in China has obtained positive top-line results. Compared with placebo, all dose groups of HRS9531 (2mg, 4mg, 6mg) achieved superiority in the co-primary endpoints and all key secondary endpoints. Hengrui Medicine said that the company plans to submit a new drug application (NDA) for HRS9531 injection for long-term weight management in China in the near future, and Kailera Therapeutics is promoting the global clinical development of HRS9531 (KAI-9531).

According to Hengrui Medicine , HRS9531 is aA self-developed GLP-1/GIP dual receptor agonist. To date, HRS9531 has been tested in a number of clinical trials. HRS9531-301 is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study (NCT06396429).

As an innovative international pharmaceutical company focusing on R&D, production and promotion of high-quality drugs, Hengrui Medicine said that in its more than 50 years of development, the company has always adhered to the original intention of "patient-centered", continued to tackle drug research and development, and continuously expanded the possible frontiers in order to overcome diseases, improve the quality of life and prolong life, and is committed to using the power of science and technology to benefit patients around the world. The company's business areas cover tumors, metabolic and cardiovascular diseases, immune and respiratory diseases, neuroscience, etc., and currently has 23 Class 1 innovative drugs approved for marketing in China., 4 Class 2 new drugs, and more than 90 independent innovation products are under clinical development. About 400 clinical trials are being conducted at home and abroad.

https://finance.eastmoney.com/a/202507163458727226.html